The FDA Grants Regenerative Medicine Advanced Therapy Designation to Autolus Therapeutics' Obecabtagene Autoleucel for Systemic Lupus Erythematosus and Lupus Nephritis
The next data update from the Phase 1 CARLYSLE trial in patients with SLE has been submitted for presentation at the American College of Rheumatology (ACR) Annual Meeting in the fourth quarter of 2026. LUMINA, the
The FDA gave Autolus Therapeutics' new medicine a special fast-track label for treating a serious disease called lupus. This means the company's medicine showed enough promise that regulators want to help speed it up—a good sign, but they still need to see more proof it actually works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.